{"disease":{"id":"cin1","name":"cin1"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04422366","title":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT05584332","title":"A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":3131,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT04425291","title":"Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1680,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT05027776","title":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1348,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT05372016","title":"Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT05916911","title":"Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Catalysis SL","has_results":false},{"nct_id":"NCT04607850","title":"Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"Barinthus Biotherapeutics","has_results":false},{"nct_id":"NCT03676101","title":"Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT06188104","title":"Efficacy of Topical 95% TCA in the Treatment of CIN 1 or Less After Low-grade Abnormality of Screening Test","phase":"PHASE2, PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Department of Medical Services Ministry of Public Health of Thailand","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}